Pfizer reports 14% YoY growth in revenue at Rs694.16cr; stock tumbles 2%

4 Feb 2022 , 12:44 PM

Pfizer Limited announced its results for the quarter ended December 2021 and has reported a total income of Rs 694.16 crore for Q3 FY’22 as against Rs 608.06 crore for Q3 FY’21, reporting growth of 14.16% YoY. Its total income for the 9M period ended December 2021 was reported at Rs 2,106.86 crore as against Rs 1,747.71 crore for the previous 9M period, registering a growth of 20.54% YoY.

Pfizer was trading at Rs 4,476.55 per piece against its previous closing price of Rs 4,568.05 per piece, down by Rs 91.50 or 2%. It touched the day’s low of Rs 4,462.50 so far.

The company’s PBT stood at Rs 184.09 crore for December 2021 quarter, as against Rs 180.26 crore for the previous corresponding quarter, up by 2.12% YoY. While its PAT expanded marginally by 2% YoY at Rs 143.91 crore for Q3 FY’22 as against Rs 141.24 crore for the same quarter last year.

PBT for the 9M period ended December 2021 stood at Rs 627.78 crore against Rs 536.63 crore for the corresponding 9M period, up by 17% YoY.

The company’s PAT for the 9M period ended December 2021 stood at Rs 486.77 crores as against Rs 397.06 crore for the corresponding 9M period, reflecting a growth of 22.60% on-year.